Biologic “Functional Equivalence” Being Considered By Insurers – WellPoint
Executive Summary
Managed care plans increasingly are moving toward selecting preferred biologic agents within a therapeutic class, WellPoint VP & Chief Pharmacy Officer Robert Seidman said
You may also be interested in...
Specialty Drug “Value-Based” Formulary Tiering Needs Transparency – AMA
The American Medical Association is concerned that "value-based" formulary tiering structures will lack sufficient transparency regarding patients' out-of-pocket costs for specialty pharmaceuticals
Specialty Drug “Value-Based” Formulary Tiering Needs Transparency – AMA
The American Medical Association is concerned that "value-based" formulary tiering structures will lack sufficient transparency regarding patients' out-of-pocket costs for specialty pharmaceuticals
Zocor Exclusivity: Ranbaxy Needs Quick Win In Suit Seeking Patent Re-Listing
Ranbaxy needs a relatively quick win in its lawsuit against FDA if it hopes to benefit from the 180-day exclusivity it is claiming for Zocor 80 mg